Kirk Gregory D, Merlo Christian, O' Driscoll Peter, Mehta Shruti H, Galai Noya, Vlahov David, Samet Jonathan, Engels Eric A
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Clin Infect Dis. 2007 Jul 1;45(1):103-10. doi: 10.1086/518606. Epub 2007 May 22.
Human immunodeficiency virus (HIV)-infected persons have an elevated risk for lung cancer, but whether the increase reflects solely their heavy tobacco use remains an open question.
The Acquired Immunodeficiency Syndrome (AIDS) Link to the Intravenous Experience Study has prospectively observed a cohort of injection drug users in Baltimore, Maryland, since 1988, using biannual collection of clinical, laboratory, and behavioral data. Lung cancer deaths were identified through linkage with the National Death Index. Cox proportional hazards regression was used to examine the effect of HIV infection on lung cancer risk, controlling for smoking status, drug use, and clinical variables.
Among 2086 AIDS Link to the Intravenous Experience Study participants observed for 19,835 person-years, 27 lung cancer deaths were identified; 14 of the deaths were among HIV-infected persons. All but 1 (96%) of the patients with lung cancer were smokers, smoking a mean of 1.2 packs per day. Lung cancer mortality increased during the highly active antiretroviral therapy era, compared with the pre-highly active antiretroviral therapy period (mortality rate ratio, 4.7; 95% confidence interval, 1.7-16). After adjusting for age, sex, smoking status, and calendar period, HIV infection was associated with increased lung cancer risk (hazard ratio, 3.6; 95% confidence interval, 1.6-7.9). Preexisting lung disease, particularly noninfectious diseases and asthma, displayed trends for increased lung cancer risk. Illicit drug use was not associated with increased lung cancer risk. Among HIV-infected persons, smoking remained the major risk factor; CD4 cell count and HIV load were not strongly associated with increased lung cancer risk, and trends for increased risk with use of highly active antiretroviral therapy were not significant.
HIV infection is associated with significantly increased risk for developing lung cancer, independent of smoking status.
感染人类免疫缺陷病毒(HIV)的个体患肺癌的风险升高,但这种增加是否仅反映了他们大量吸烟的情况仍无定论。
自1988年以来,“艾滋病与静脉注射经历研究”前瞻性地观察了马里兰州巴尔的摩市的一组注射吸毒者,每半年收集临床、实验室和行为数据。通过与国家死亡指数联动来确定肺癌死亡病例。采用Cox比例风险回归分析来检验HIV感染对肺癌风险的影响,并对吸烟状况、药物使用情况和临床变量进行控制。
在2086名“艾滋病与静脉注射经历研究”参与者中,共观察了19835人年,确定有27例肺癌死亡;其中14例死亡发生在HIV感染者中。除1例(96%)肺癌患者外,其余均为吸烟者,平均每天吸烟1.2包。与高效抗逆转录病毒治疗前相比,在高效抗逆转录病毒治疗时代肺癌死亡率有所上升(死亡率比值为4.7;95%置信区间为1.7 - 16)。在调整年龄、性别、吸烟状况和日历时间后,HIV感染与肺癌风险增加相关(风险比为3.6;95%置信区间为1.6 - 7.9)。既往肺部疾病,尤其是非感染性疾病和哮喘,显示出肺癌风险增加的趋势。非法药物使用与肺癌风险增加无关。在HIV感染者中,吸烟仍然是主要危险因素;CD4细胞计数和HIV病毒载量与肺癌风险增加没有强烈关联,使用高效抗逆转录病毒治疗导致风险增加的趋势并不显著。
HIV感染与患肺癌的风险显著增加相关,与吸烟状况无关。